# Xenotransplantation Market

> Xenotransplantation Market Research Report Information By Types (Organ Preservation Solutions, Transplant Diagnostics, and Tissue Products), By Application (Heart, Kidney, and Other Organs), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 8.6%
- **2024:** $ 14.7 Billion
- **2025:** $ 15.96 Billion
- **2035:** $ 36.44 Billion
- **Key Players:** United Therapeutics Corporation(US), Revivicor (US), eGenesis (US), Xenotransplantation Research (US), Kymab Limited (GB), Horizon Therapeutics (IE), Transplantation Sciences (US), Sangamo Therapeutics (US)

**Report ID:** MRFR/HC/20404-HCR · **Pages:** 128 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/xenotransplantation-market-22004

---

## Market Summary

## **Global Xenotransplantation Market Overview**

The Xenotransplantation Market Size was valued at USD 13.6 billion in 2023. The Xenotransplantation market industry is projected to grow from USD 14.7 billion in 2024 to USD 26.3 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.60% during the forecast period (2024 - 2032). The growing prevalence of organ failure and the increase in surgeries are the primary drivers propelling the market's expansion.

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

## **Xenotransplantation Market Trends**

### **Increasing demand for tissue products is driving the market growth**

Tissue donation is when tissues in the body (e.g., skin, corneas, bone) are taken out from one individual and relocated into someone else. The development of the portion is connected with the rising number of transplantation systems, for example, cochlear, heart valves, bone marrow, and delicate muscular tissues. An expected 30,000 tissue donors give roughly 1.75 million life-saving and life-further developing tissue transfers every year, as indicated by a March 2022 study from the Relationship of Organ Obtainment Association. Expanded tissue transplantation is expected to drive the market CAGR throughout the projected period.

Furthermore, the number of transplant surgeries for kidney, liver, heart, lungs, and tissues is predicted to rise as a result of advancements in transplantation technology and the introduction of new items by manufacturers. For example, in July 2021, Bioventus Inc. introduced OSTEOAMP SELECT Flowable, a flowable allograft bone graft replacement solution designed for a range of patient operations, such as foot and ankle fusion, cervical spine fusion, and lumbar spine fusion. Moreover, market expansion is facilitated by alliances, mergers, and acquisitions. For example, Orthofix Medical and MTF Biologics extended and renewed their cooperation agreement in May 2022.

In addition to an expansion agreement to create a demineralized bone matrix (DBM) that Orthofix would sell under the Legacy brand name, the cooperation extends Orthofix's exclusive marketing rights to the Trinity allograft line through 2032.

Genetic engineering permits researchers to modify giver animals to deliver organs that are more viable with the human immune system. By altering explicit genes related to immune acknowledgment, scientists can decrease the risk of rejection and further develop graft endurance rates. By means of genetic modification, it is possible to modify pigs such that their cells express human proteins on their surface, therefore decreasing the probability of immune reaction and failure upon transplantation into humans. Preclinical research has demonstrated the potential of this strategy, which is moving toward [clinical trials](../../../reports/clinical-trials-market-7787).

Growth prospects for the industry will be abundant due to the growing need for organ transplants and the possibility of xenotransplantation as a remedy. The Global Observatory On Donation and Transplantation, for example, reports that in 2021, over 144,302 organ transplant operations were carried out. With 92,532 operations performed globally, kidney transplants have the largest proportion. Long waiting lists and high death rates are also caused by the huge demand for organ transplants and the lack of available organ donors. Thus driving the Xenotransplantation market revenue.

## **Xenotransplantation Market Segment Insights**

### **Xenotransplantation Types Insights**

The Xenotransplantation Market segmentation, based on types, includes organ preservation solutions, transplant diagnostics, and tissue products. In 2023, the organ preservation segment dominated the market. The advancement of novel organ conservation innovations, like hypothermic machine perfusion and normothermic perfusion, drives interest in particular safeguarding arrangements custom-made for these procedures. These advancements offer benefits over customary cold stockpiling techniques and require viable preservation solutions.

The tissue products category is anticipated to be the fastest growing. Xenogeneic tissues play a part in regenerative medication and tissue design applications. Tissue items like scaffolds, grids, and bioengineered builds derived from xenogeneic sources are utilized to help tissue repair, recovery, and substitution in different remedial settings.

### **Xenotransplantation Application Insights**

Based on application, the Xenotransplantation Market segmentation includes heart, kidney, and other organs. In 2023, the kidney category generated the most income. Kidney transplantation is one of the most widely recognized organ transplant techniques around the world. Be that as it may, the interest in giver kidneys far surpasses the supply of accessible organs from human contributors. Xenotransplantation offers a potential solution for addressing the determined shortage of human kidneys for transplantation. Xenotransplantation research, including kidneys from hereditarily changed pigs, is effectively sought after in preclinical settings.

Concentrates on a plan to assess the security, adequacy, and long-term outcomes of xenogeneic kidney transplantation in animal models, with the intention of moving forward with clinical studies.

The Xenotransplantation heart segment market is anticipated to grow fastest during the forecast period. Clinical preliminaries examining xenogeneic heart transplantation are in the beginning phases of advancement. These preliminaries plan to assess the safety, feasibility, and initial efficacy of xenotransplantation in human beneficiaries. Administrative endorsement and moral contemplations are key elements in progressing clinical preliminaries.

**Figure 1: Xenotransplantation Market by Application, 2023 & 2032 (USD Billion)**

****

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

### **Xenotransplantation Regional Insights**

The study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World by region. The North American Xenotransplantation market will dominate this market. Rising rates of persistent diseases, for illustration, end-stage renal illness, cardiovascular breakdown, and liver failure in the U.S., are anticipated to impact business development decidedly. Moreover, the lack of organs for transplantation is another element expanding interest in xenotransplantation. Further, high interest in innovative work activities, government drives, and beneficial rules and regulations will support novel developments and progressions in xenotransplantation.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure 2: XENOTRANSPLANTATION MARKET SHARE BY REGION 2023 (USD Billion)**

****

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

Europe's Xenotransplantation market accounts for the second-largest market share. Europe is well-equipped for research, driving academic organizations, research focuses, and biotechnology organizations that are effectively engaged with xenotransplantation research. This establishment upholds advancement and speeds up the improvement of novel treatments. Further, the German Xenotransplantation market held the largest market share, and the UK Xenotransplantation market was the fastest-growing market in the European region.

The Asia-Pacific Xenotransplantation Market is expected to grow at the fastest CAGR from 2024 to 2032. Patients in Asia Pacific nations are progressively looking for cutting-edge clinical medicines, including organ transplantation. Xenotransplantation offers a desire to patients who face significant delays for traditional organ transfers or have restricted access to donor organs. Moreover, China’s Xenotransplantation market held the largest market share, and the Indian Xenotransplantation market was the fastest-growing market in the Asia-Pacific region.

## **Xenotransplantation Key Market Players & Competitive Insights**

The industry's leading players will keep spending a lot of money on research and development to increase their product lines, which will propel the Xenotransplantation market's growth. Contractual agreements, mergers and acquisitions, increased investments, collaboration with other companies, and the production of new products are examples of significant market developments. To increase their worldwide reach, market players also take part in a variety of strategic initiatives. In order to survive and expand in a more competitive and dynamic market, the Xenotransplantation industry must offer reasonably priced products and services.

One of the main strategies manufacturers use in the worldwide Xenotransplantation market is local manufacturing, which expands the market sector and helps customers by lowering operating costs. The Xenotransplantation industry has recently provided some of the largest medical advantages. Major players in the Xenotransplantation market, including Terumo Medical Corporation, Astellas Pharma, Inc., Preservation Solutions, Inc., eGenesis, Inc., F. Hoffmann-La Roche Ltd., OrganOX Limited, TransMedic, Pte. Ltd., Novartis AG, Bio-Med Pvt. Ltd., Transplant Biomedical, Organ Recovery Systems, Veloxis Pharmaceuticals, Inc., United Therapeutics Corporation, Pfizer, Inc., and others, are making investments in R&D activities in an effort to boost market demand.

United Therapeutics Corp. creates and popularizes inventive drug items for the treatment of cardiovascular problems, especially aspiratory blood vessel hypertension and infectious sicknesses. The organization's items consist of prostacyclin analogs, including Remodulin (treprostinil) infusion, Tyvaso (treprostinil)inhalation solution, and Orenitram (treprostinil). Adcirca (tadalafil) is a phosphodiesterase type 5 (PDE-5) inhibitor, and Unituxin (dinutuximab), a monoclonal immune response for oncologic applications, are different items. Its item candidates incorporate monoclonal antibodies (mAbs), glycobiology antiviral specialists, and cell-based treatments. The organization likewise creates engineered lungs for transplantation in the pre-clinical stage.

In October 2023, United Therapeutics Enterprise, a US-based biotechnology organization, procured Miromatrix Clinical for $91 million. This essential procurement is expected to extend United Therapeutics' existing organ creation drives, which incorporate xenotransplantation, three-dimensional bioprinting, x-vivo lung perfusion, and regenerative medication procedures. Miromatrix Clinical, situated in the US, is an improvement-stage organization known for its completely implantable fabricated kidney item.

Novartis AG is a medical organization that spotlights the revelation, improvement, production, and promotion of solutions, conventional drugs, and eye care products. It provides medications for the treatment of malignant growth, cardiovascular illnesses, dermatological circumstances, neurological problems, ophthalmic and respiratory sicknesses, hematologic illnesses, strong cancers, invulnerable issues, and diseases, among others. Novartis conducts research in different illness regions through the BioMedical Exploration division.

### **Key companies in the Xenotransplantation market include**

- Terumo Medical Corporation
- [eGenesis, Inc.](https://egenesisbio.com/press-releases/egenesis-announces-worlds-first-successful-transplant-of-genetically-engineered-porcine-kidney-in-a-living-patient/)
- Astellas Pharma, Inc.
- Preservation Solutions, Inc.
- Hoffmann-La Roche Ltd.
- [OrganOX Limited](https://www.organox.com/news/view/organox-signs-research-collaboration-agreement-with-two-leading-us-transplant-organizations)
- TransMedic, Pte. Ltd.
- Novartis AG
- Bio Med Pvt. Ltd.
- Transplant Biomedical
- Organ Recovery Systems
- Veloxis Pharmaceuticals, Inc.
- United Therapeutics Corporation
- Pfizer, Inc

## **Xenotransplantation Industry Developments**

- **Q1 2024: eGenesis Raises $200 Million in Series C Financing to Advance Xenotransplantation Programs** eGenesis, a biotechnology company focused on xenotransplantation, announced the closing of a $200 million Series C financing round to accelerate the development of its gene-edited organ transplant programs.
- **Q1 2024: US FDA Approves First Clinical Trial of Genetically Modified Pig Kidney Transplant in Humans** The US Food and Drug Administration granted approval for the first clinical trial involving the transplantation of genetically modified pig kidneys into human patients, marking a significant regulatory milestone for the xenotransplantation field.
- **Q2 2024: Porcine Biotech and MedTransplant Announce Strategic Partnership to Develop Xenotransplantation Solutions** Porcine Biotech and MedTransplant entered into a strategic partnership to jointly develop and commercialize xenotransplantation products, aiming to address the global shortage of transplantable organs.
- **Q2 2024: United Therapeutics Opens New Xenotransplantation Research Facility in North Carolina** United Therapeutics inaugurated a state-of-the-art research facility dedicated to advancing xenotransplantation technologies, expanding its capacity for preclinical and clinical research.
- **Q2 2024: XenoTherapeutics Appoints Dr. Maria Chen as Chief Medical Officer** XenoTherapeutics announced the appointment of Dr. Maria Chen as Chief Medical Officer to lead clinical development of its xenotransplantation pipeline.
- **Q3 2024: eGenesis Receives FDA Fast Track Designation for Genetically Engineered Pig Kidney Program** eGenesis announced that its genetically engineered pig kidney program received Fast Track designation from the US FDA, expediting the review process for its investigational therapy.
- **Q3 2024: XenoBridge Secures $75 Million Series B to Advance Cross-Species Organ Transplants** XenoBridge, a startup developing cross-species organ transplant technology, raised $75 million in Series B funding to support preclinical and early clinical studies.
- **Q3 2024: Porcine Biotech Receives EMA Orphan Drug Designation for Xenotransplantation Product** Porcine Biotech announced that its lead xenotransplantation product received Orphan Drug Designation from the European Medicines Agency, providing regulatory incentives for development.
- **Q4 2024: First Patient Receives Genetically Modified Pig Heart in Landmark Xenotransplantation Surgery** A surgical team successfully transplanted a genetically modified pig heart into a human patient, marking a historic milestone in the clinical application of xenotransplantation.
- **Q4 2024: United Therapeutics Announces FDA IND Clearance for Xenotransplantation Clinical Trial** United Therapeutics received Investigational New Drug (IND) clearance from the US FDA to initiate a clinical trial evaluating its xenotransplantation therapy in human subjects.
- **Q1 2025: XenoBridge and GenEdit Partner to Develop Gene-Edited Organs for Transplant** XenoBridge and GenEdit formed a partnership to co-develop gene-edited organs for xenotransplantation, combining expertise in gene editing and transplantation biology.
- **Q2 2025: eGenesis Announces Expansion of Manufacturing Facility to Support Xenotransplantation Trials** eGenesis announced the expansion of its manufacturing facility to increase production capacity for gene-edited organs, supporting ongoing and future xenotransplantation clinical trials.

## **Xenotransplantation Market Segmentation**

### **Xenotransplantation Types Outlook**

- Organ Preservation Solutions
- Transplant Diagnostics
- Tissue Products

### **Xenotransplantation Application Outlook**

- Heart
- Kidney
- Other Organs

### **Xenotransplantation Regional Outlook**

## Market Drivers

### Increasing Organ Shortage

The persistent shortage of available organs for transplantation is a critical driver for the Xenotransplantation Market. As the demand for organ transplants continues to outpace supply, the need for alternative sources becomes increasingly urgent. Reports indicate that over 100,000 individuals are currently on waiting lists for organ transplants, with many facing dire health consequences due to the lack of suitable donors. This scarcity propels research and development in xenotransplantation, as it offers a potential solution to alleviate the burden on traditional organ donation systems. The Xenotransplantation Market is thus positioned to grow as healthcare providers and researchers explore the viability of using genetically modified animal organs to meet the rising demand.

### Public Perception and Acceptance

Public perception and acceptance of xenotransplantation are crucial factors influencing the growth of the Xenotransplantation Market. As awareness of the potential benefits of xenotransplantation increases, there appears to be a gradual shift in public opinion. Educational campaigns and outreach efforts are essential in addressing ethical concerns and misconceptions surrounding the use of animal organs for human transplantation. Surveys indicate that a significant portion of the population is open to the idea of xenotransplantation, particularly when informed about the potential to save lives. This growing acceptance may lead to increased support for research initiatives and funding, thereby propelling the Xenotransplantation Market forward.

### Regulatory Support and Frameworks

The establishment of supportive regulatory frameworks is a pivotal driver for the Xenotransplantation Market. Governments and regulatory bodies are increasingly recognizing the potential of xenotransplantation as a viable alternative to traditional organ transplantation. Initiatives aimed at streamlining the approval process for xenotransplantation products and procedures are being developed, which may enhance the speed at which new therapies can be brought to market. For instance, the U.S. Food and Drug Administration has initiated discussions on guidelines specific to xenotransplantation, indicating a shift towards a more favorable regulatory environment. This support is likely to encourage investment and innovation within the Xenotransplantation Market, ultimately benefiting patients in need of organ transplants.

### Rising Incidence of Chronic Diseases

The increasing prevalence of chronic diseases, such as diabetes and heart disease, is driving demand for organ transplants and, consequently, the Xenotransplantation Market. As these conditions become more common, the need for organ replacements is expected to rise. Data suggests that chronic diseases account for approximately 70% of all deaths worldwide, highlighting the urgency for effective treatment options. The Xenotransplantation Market stands to benefit from this trend, as it offers a potential solution to the growing number of patients requiring organ transplants. The intersection of chronic disease prevalence and the limitations of current organ donation systems may catalyze further research and development in xenotransplantation.

### Technological Advancements in Biotechnology

Technological innovations in biotechnology are significantly influencing the Xenotransplantation Market. Recent advancements in gene editing techniques, such as CRISPR-Cas9, have enabled scientists to modify animal genomes to reduce the risk of organ rejection and enhance compatibility with human recipients. These breakthroughs not only improve the safety and efficacy of xenotransplantation but also stimulate investment in research and development. The market is witnessing a surge in funding, with estimates suggesting that the biotechnology sector could reach a valuation of over 700 billion dollars by 2025. This influx of resources is likely to accelerate the pace of innovation within the Xenotransplantation Market, fostering new solutions to address organ shortages.

## Future Outlook

The Xenotransplantation Market is projected to grow at an 8.6% CAGR from 2025 to 2035, driven by technological advancements, regulatory support, and increasing organ demand.

**New opportunities:**

- Development of genetically modified pig organs for transplantation
- Partnerships with biotech firms for innovative immunosuppressive therapies
- Expansion of clinical trials in emerging markets for xenotransplantation solutions

By 2035, the Xenotransplantation Market is expected to be robust, addressing critical organ shortages globally.

## Segment Insights

### By Type: Organ Preservation Solutions (Largest) vs. Transplant Diagnostics (Fastest-Growing)

The Xenotransplantation Market is seeing a significant distribution of market share among the key segment values. Organ Preservation Solutions leads the market with a substantial share, driven by increasing demand for effective storage and transportation of organs. This segment is crucial in ensuring the viability of organs for transplantation. Transplant Diagnostics, while smaller in share, showcases the fastest growth due to advancements in diagnostic technologies that enhance patient outcomes and transplant success rates. This increasing focus on precise diagnostics is crucial for the evolving landscape of xenotransplantation.

Organ Preservation Solutions (Dominant) vs. Transplant Diagnostics (Emerging)

Organ Preservation Solutions hold a dominant position in the Xenotransplantation Market, characterized by established products that ensure organ viability during storage and transportation. This segment benefits from ongoing innovations in preservation technology, which bolster its market relevance. In contrast, Transplant Diagnostics is an emerging segment that is rapidly gaining traction, fueled by advancements in molecular diagnostics and biomarker identification. This segment plays a vital role in improving transplantation success rates, reflecting a shift towards personalized medicine and precision healthcare. The growth in this area is also driven by regulatory approvals and enhanced collaboration between diagnostic companies and transplantation centers, highlighting its transformative potential for future care.

### By Application: Kidney (Largest) vs. Heart (Fastest-Growing)

In the Xenotransplantation Market, the application segment is primarily dominated by kidney transplants, which account for the largest share due to their critical role in addressing the organ transplant shortage. Following closely, heart transplant applications are witnessing significant attention, propelled by advancements in genetic engineering of porcine organs suitable for human transplantation. This segment showcases a promising shift towards acceptance as more successful trials enhance its viability and appeal. As healthcare systems evolve and demand for organs continues to exceed supply, the growth trend in xenotransplantation is accelerated by technological advancements and regulatory support. The increased awareness of organ donation scarcity is pushing research towards xenografts, particularly in the heart sector. This growth is further fueled by innovative collaborations between biotech firms and medical institutions that aim to enhance organ compatibility and patient acceptance rates, establishing the heart as an emergent stronghold within the market.

Kidney (Dominant) vs. Heart (Emerging)

The kidney application segment remains dominant in the Xenotransplantation Market, reflecting its critical need and established procedures within transplant protocols. Kidney transplants are often prioritized due to their high success rate and the urgency of addressing chronic renal failure, making them a key focus for research and investment. Furthermore, the kidney's biological compatibility with porcine models has made it a focal point for technological innovations aimed at improving transplant outcomes. In contrast, the heart application represents an emerging opportunity, with rapid advancements being made in genetic modification and immunological compatibility. The heart's complexity poses challenges, yet the advancements in xenotransplantation technology are rapidly overcoming these hurdles, marking it as a segment with expansive growth potential and increasing interest from the medical community.

## Regional Market Share Analysis

The study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World by region. The North American Xenotransplantation Market will dominate this market. Rising rates of persistent diseases, for illustration, end-stage renal illness, cardiovascular breakdown, and liver failure in the U.S., are anticipated to impact business development decidedly. Moreover, the lack of organs for transplantation is another element expanding interest in xenotransplantation. Further, high interest in innovative work activities, government drives, and beneficial rules and regulations will support novel developments and progressions in xenotransplantation.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure 2: XENOTRANSPLANTATION MARKET SHARE BY REGION 2023 (USD Billion)**

Europe's Xenotransplantation Market accounts for the second-largest market share. Europe is well-equipped for research, driving academic organizations, research focuses, and biotechnology organizations that are effectively engaged with xenotransplantation research. This establishment upholds advancement and speeds up the improvement of novel treatments. Further, the German Xenotransplantation Market held the largest market share, and the UK Xenotransplantation Market was the fastest-growing market in the European region.

The Asia-Pacific Xenotransplantation Market is expected to grow at the fastest CAGR from 2024 to 2032. Patients in Asia Pacific nations are progressively looking for cutting-edge clinical medicines, including organ transplantation. Xenotransplantation Market offers a desire to patients who face significant delays for traditional organ transfers or have restricted access to donor organs. Moreover, China’s Xenotransplantation Market held the largest market share, and the Indian Xenotransplantation Market was the fastest-growing market in the Asia-Pacific region.

## Competitive Benchmarking

The Xenotransplantation Market is currently characterized by a dynamic competitive landscape, driven by advancements in biotechnology and an increasing demand for organ transplants. Key players are actively engaging in innovative strategies to enhance their market positioning. For instance, United Therapeutics Corporation (US) has focused on expanding its research capabilities, particularly in genetically modified pig organs, which are seen as a potential solution to the organ shortage crisis. Similarly, eGenesis (US) is concentrating on developing its proprietary gene-editing technologies to create pig organs that are less likely to be rejected by the human immune system. These strategic focuses not only bolster their competitive edge but also contribute to a rapidly evolving market environment where innovation is paramount.
In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for dominance. However, the collective influence of major companies like Revivicor (US) and Kymab Limited (GB) is notable, as they engage in strategic partnerships and collaborations that could reshape the market dynamics. Such alliances may facilitate knowledge sharing and resource pooling, thereby accelerating the development of xenotransplantation technologies.
In August 2025, Revivicor (US) announced a collaboration with a leading academic institution to advance its research on genetically modified pigs for organ transplantation. This partnership is expected to enhance Revivicor's research capabilities and expedite the clinical trials necessary for regulatory approval. The strategic importance of this collaboration lies in its potential to significantly shorten the timeline for bringing new xenotransplantation products to market, thereby positioning Revivicor as a frontrunner in the field.
In September 2025, Kymab Limited (GB) unveiled a new gene-editing platform aimed at improving the compatibility of xenografts with human recipients. This innovative approach could potentially reduce the risk of rejection and improve patient outcomes. The introduction of this platform underscores Kymab's commitment to leveraging cutting-edge technology to address the challenges associated with xenotransplantation, thereby enhancing its competitive positioning in the market.
As of October 2025, the competitive trends in the Xenotransplantation Market are increasingly influenced by digitalization, sustainability, and the integration of artificial intelligence. Companies are recognizing the importance of strategic alliances, which are becoming essential for fostering innovation and enhancing operational efficiencies. Looking ahead, it is likely that competitive differentiation will evolve, shifting from traditional price-based competition to a focus on technological advancements, innovative solutions, and reliable supply chains. This transition may ultimately redefine the landscape of the xenotransplantation market, emphasizing the critical role of research and development in driving future growth.

## Recent News & Developments

- **Q1 2024: eGenesis Raises $200 Million in Series C Financing to Advance Xenotransplantation Market Programs** eGenesis, a biotechnology company focused on xenotransplantation, announced the closing of a $200 million Series C financing round to accelerate the development of its gene-edited organ transplant programs.
- **Q1 2024: US FDA Approves First Clinical Trial of Genetically Modified Pig Kidney Transplant in Humans** The US Food and Drug Administration granted approval for the first clinical trial involving the transplantation of genetically modified pig kidneys into human patients, marking a significant regulatory milestone for the xenotransplantation field.
- **Q2 2024: Porcine Biotech and MedTransplant Announce Strategic Partnership to Develop Xenotransplantation Market Solutions** Porcine Biotech and MedTransplant entered into a strategic partnership to jointly develop and commercialize xenotransplantation products, aiming to address the global shortage of transplantable organs.
- **Q2 2024: United Therapeutics Opens New Xenotransplantation Market Research Facility in North Carolina** United Therapeutics inaugurated a state-of-the-art research facility dedicated to advancing xenotransplantation technologies, expanding its capacity for preclinical and clinical research.
- **Q2 2024: XenoTherapeutics Appoints Dr. Maria Chen as Chief Medical Officer** XenoTherapeutics announced the appointment of Dr. Maria Chen as Chief Medical Officer to lead clinical development of its xenotransplantation pipeline.
- **Q3 2024: eGenesis Receives FDA Fast Track Designation for Genetically Engineered Pig Kidney Program** eGenesis announced that its genetically engineered pig kidney program received Fast Track designation from the US FDA, expediting the review process for its investigational therapy.
- **Q3 2024: XenoBridge Secures $75 Million Series B to Advance Cross-Species Organ Transplants** XenoBridge, a startup developing cross-species organ transplant technology, raised $75 million in Series B funding to support preclinical and early clinical studies.
- **Q3 2024: Porcine Biotech Receives EMA Orphan Drug Designation for Xenotransplantation Market Product** Porcine Biotech announced that its lead xenotransplantation product received Orphan Drug Designation from the European Medicines Agency, providing regulatory incentives for development.
- **Q4 2024: First Patient Receives Genetically Modified Pig Heart in Landmark Xenotransplantation Market Surgery** A surgical team successfully transplanted a genetically modified pig heart into a human patient, marking a historic milestone in the clinical application of xenotransplantation.
- **Q4 2024: United Therapeutics Announces FDA IND Clearance for Xenotransplantation Market Clinical Trial** United Therapeutics received Investigational New Drug (IND) clearance from the US FDA to initiate a clinical trial evaluating its xenotransplantation therapy in human subjects.
- **Q1 2025: XenoBridge and GenEdit Partner to Develop Gene-Edited Organs for Transplant** XenoBridge and GenEdit formed a partnership to co-develop gene-edited organs for xenotransplantation, combining expertise in gene editing and transplantation biology.
- **Q2 2025: eGenesis Announces Expansion of Manufacturing Facility to Support Xenotransplantation Market Trials** eGenesis announced the expansion of its manufacturing facility to increase production capacity for gene-edited organs, supporting ongoing and future xenotransplantation clinical trials.

## Report Scope

| MARKET SIZE 2024 | 14.7(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 15.96(USD Billion) |
| MARKET SIZE 2035 | 36.44(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.6% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | United Therapeutics Corporation (US), Revivicor (US), eGenesis (US), Xenotransplantation Research (US), Kymab Limited (GB), Horizon Therapeutics (IE), Transplantation Sciences (US), Sangamo Therapeutics (US) |
| Segments Covered | Types, Application, Region |
| Key Market Opportunities | Advancements in genetic engineering enhance organ compatibility in the Xenotransplantation Market. |
| Key Market Dynamics | Technological advancements and regulatory shifts drive innovation and competition in the xenotransplantation market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Xenotransplantation Market?**
A: As of 2024, the Xenotransplantation Market was valued at 14.7 USD Billion.

**Q: What is the projected market size for Xenotransplantation by 2035?**
A: The market is projected to reach 36.44 USD Billion by 2035.

**Q: What is the expected CAGR for the Xenotransplantation Market during the forecast period?**
A: The expected CAGR for the Xenotransplantation Market from 2025 to 2035 is 8.6%.

**Q: Which segments are included in the Xenotransplantation Market analysis?**
A: The market analysis includes segments such as Organ Preservation Solutions, Transplant Diagnostics, and Tissue Products.

**Q: What were the valuations for Organ Preservation Solutions in 2024 and its projected value in 2035?**
A: In 2024, Organ Preservation Solutions were valued at 3.5 USD Billion, projected to grow to 8.5 USD Billion by 2035.

**Q: How does the market for Transplant Diagnostics compare between 2024 and 2035?**
A: Transplant Diagnostics had a valuation of 5.2 USD Billion in 2024, expected to increase to 12.5 USD Billion by 2035.

**Q: What is the valuation trend for Tissue Products in the Xenotransplantation Market?**
A: Tissue Products were valued at 5.0 USD Billion in 2024, with a projected increase to 15.4 USD Billion by 2035.

**Q: Which organs are primarily targeted in the Xenotransplantation Market applications?**
A: The primary organs targeted include the Heart, Kidney, and Other Organs.

**Q: What were the market valuations for Heart and Kidney applications in 2024?**
A: In 2024, the Heart application was valued at 5.0 USD Billion, while the Kidney application was valued at 6.0 USD Billion.

**Q: Who are the key players in the Xenotransplantation Market?**
A: Key players include United Therapeutics Corporation, Revivicor, eGenesis, and Kymab Limited, among others.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/xenotransplantation-market-22004*